- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hereditary angioedema (HAE)
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 742KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 307KB)
Lanadelumab – November 2024
Lanadelumab; Injection 150 mg in 1 mL single use pre-filled syringe; Takhzyro®
Last updated
30 May 2025